Baird lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $155 from $167 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where they were light on revenue but 2025 guidance is maintained.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $216 from $213 at BofA
- Jazz Pharmaceuticals price target lowered to $166 from $183 at Morgan Stanley
- Optimistic Growth Outlook for Jazz Pharmaceuticals Amid Strategic Product Focus and Pipeline Catalysts
- Positive Outlook for Jazz Pharmaceuticals: Buy Rating Affirmed Amid Strategic Moves and Upcoming Catalysts
- Jazz Pharmaceuticals: Buy Rating Affirmed Amid Growth Potential and Transformative Catalysts